{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"86.2","upperLimit":"92.9","value":"90.1"},{"groupId":"OG001","lowerLimit":"49.0","upperLimit":"59.7","value":"54.5"}]}],"title":"DFS rate at 2 years (%)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"79.9","upperLimit":"88.1","value":"84.5"},{"groupId":"OG001","lowerLimit":"39.0","upperLimit":"49.7","value":"44.4"}]}],"title":"DFS rate at 3 years (%)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"53.1","upperLimit":"67.8","value":"60.9"},{"groupId":"OG001","lowerLimit":"28.0","upperLimit":"39.2","value":"33.6"}]}],"title":"DFS rate at 5 years (%)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"339"},{"groupId":"OG001","value":"343"}],"units":"Participants"}],"description":"Defined as the percentage of patients alive and disease free at 2, 3 and 5 years, respectively, estimated from Kaplan Meier plots of the primary endpoint of DFS.","dispersionType":"95% Confidence Interval","groups":[{"description":"Taken once daily","id":"OG000","title":"AZD9291 80mg Tablet"},{"description":"Taken once daily","id":"OG001","title":"Placebo Tablet"}],"paramType":"NUMBER","populationDescription":"Full analysis set (FAS) stage IB-IIIA patients","reportingStatus":"POSTED","timeFrame":"Up to approximately 5 years after the first patient is randomized (maximum follow up of 70 months). DFS rate at 2 years (%), 3 years (%) and 5 years (%) are presented.","title":"Disease Free Survival (DFS) Rate at 2, 3 and 5 Years","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}